Trials / Completed
CompletedNCT05800249
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
A Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients With Advanced Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Shanghai HyaMab Biotech Co.,Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PE0116 | This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor |
Timeline
- Start date
- 2021-03-08
- Primary completion
- 2023-06-02
- Completion
- 2023-06-16
- First posted
- 2023-04-05
- Last updated
- 2023-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05800249. Inclusion in this directory is not an endorsement.